In prostate cancer, complete metastatic ablation of oligometastatic disease with SABR and integrated PSMA-PET may provide an alternative to early initiation of androgen deprivation therapy [61]; SBRT can also be useful in early prostate cancer in particular conditions (such as covid19 pandemics) requiring shorter treatment time [72]. The gene discussed is FOLH1; the disease is prostate cancer.